• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The oncologist >Incidence, risk factors, andmanagement of infusion-related reactions in breast cancer patients receiving trastuzumab
【24h】

Incidence, risk factors, andmanagement of infusion-related reactions in breast cancer patients receiving trastuzumab

机译：接受曲妥珠单抗的乳腺癌患者的发病率，危险因素和输注相关反应的管理

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. Trastuzumab has become a mainstay of therapy for human epidermal growth factor receptor-2 overexpressed breast cancer in nearly all stages of the disease. Like many monoclonal antibodies, trastuzumab is associated with infusionrelated reactions (IRRs) that are notwell described, and incidence varies widely between reports (0.7%-40% of patients). MaterialsandMethods. Aretrospective chart reviewof breast cancer patients who received trastuzumab was conducted. The primary objective was to describe the incidence, risk factors, and management of IRRs during the first 12 weeks of trastuzumab therapy in a general population of breast cancer patients. Results. A total of 197 patients who received trastuzumab (1,788 doses) were evaluated.Thirty-three IRRswere identified in 32 patients, resulting in an incidence of 16.2% of patients and 1.8% of doses. All IRRs were mild or moderate in severity and were successfully managed with supportive medications and/or by temporarily stopping the infusion. All patients received subsequent cycles of trastuzumab, with only one patient experiencing a subsequent reaction. Body mass index, stage of disease, and use of premedications were significantly associatedwithIRRsbymultivariatelogistic regressionanalysis. Conclusion. Overall, these results support that the vast majority of IRRs occur with the first infusion, are mild in severity, and are easily managed. In addition, risk factors were identified that may help to identify a population of patients at increased risk of IRRs who may benefit from premedication.
机译：背景。曲妥珠单抗已成为该疾病几乎所有阶段中人表皮生长因子受体2过表达的乳腺癌治疗的主要手段。像许多单克隆抗体一样，曲妥珠单抗与输注相关反应（IRR）相关联，目前还没有得到很好的描述，报告之间的发生率差异很大（0.7％-40％的患者）。材料和方法。对接受曲妥珠单抗的乳腺癌患者进行了回顾性图表审查。主要目的是描述在一般乳腺癌患者中曲妥珠单抗治疗的前12周内IRR的发生率，危险因素和处理。结果。共评估了197名接受曲妥珠单抗（1,788剂）的患者。在32例患者中鉴定出33例IRR，导致发生率分别为16.2％和1.8％。所有IRR的严重程度均为轻度或中度，并已成功通过支持药物和/或暂时停止输注治疗。所有患者均接受曲妥珠单抗的后续治疗，只有一名患者出现后续反应。通过多变量logistic回归分析，体重指数，疾病分期和药物的使用与IRRs显着相关。结论。总体而言，这些结果支持绝大多数IRR在首次输注时发生，严重程度较轻且易于管理。另外，确定了风险因素，可以帮助确定IRRs风险增加的患者群体，这些患者可能会从用药前受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号